Ab Initio Pharma, a formulation and manufacturing company, established as a spinoff by the University of Sydney in partnership with Sydney Local Health Distinct and the peak industry body, ACRS will provide innovators with a flexible platform to rapidly translate bench-top discoveries to clinical trial products and fully-fledged commercial pharmaceuticals. Importantly, Ab Initio will have R&D facilities and be able to offer its partners formulation services to develop products suitable for clinical trials.